Cargando…

Correction to “Clinical benefit of platinum doublet combination therapy in older adults with advanced non‐small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481140/ https://www.ncbi.nlm.nih.gov/pubmed/37485781 http://dx.doi.org/10.1111/1759-7714.15047

Ejemplares similares

Clinical benefit of platinum doublet combination therapy in older adults with advanced non‐small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan
por: Shimokawa, Mototsugu, et al.
Publicado: (2023)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
por: Wang, Jiun-Long, et al.
Publicado: (2021)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis
por: Ohmoto, Akihiro, et al.
Publicado: (2022)

Advances in doublet mechanics
por: Ferrari, Mauro, et al.
Publicado: (1997)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
por: Kozloff, M F, et al.
Publicado: (2012)

Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet
por: Ryu, Jeong-Seon, et al.
Publicado: (2019)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023)

Correction: Educational benefits for nurses and nursing students of the dementia supporter training program in Japan
Publicado: (2018)

Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet
por: Kozłowska, Emilia, et al.
Publicado: (2020)

Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study
por: Wang, Xiangling, et al.
Publicado: (2023)

Correction to: benefit incidence analysis in public health facilities in India: utilization and benefits at the national and state levels
por: Bowser, Diana, et al.
Publicado: (2019)

Correction: A multicenter, randomized controlled trial of individualized occupational therapy for patients with schizophrenia in Japan
por: Shimada, Takeshi, et al.
Publicado: (2018)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients
por: Liu, Di, et al.
Publicado: (2015)

Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study
por: Nasu, Izumi, et al.
Publicado: (2023)

Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets
por: Alexa, Teodora, et al.
Publicado: (2014)

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
por: Takahashi, Toshiaki, et al.
Publicado: (2021)

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

Correction for The N-DRC forms a conserved biochemical complex that maintains outer doublet alignment and limits microtubule sliding in motile axonemes
Publicado: (2013)

(18)F-FDG and (11)C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study
por: Minamimoto, Ryogo, et al.
Publicado: (2019)

Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy
por: van der Voort van Zyp, Noëlle, et al.
Publicado: (2022)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
por: Greystoke, Alastair, et al.
Publicado: (2017)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis
por: Xiao, Huai-Qing, et al.
Publicado: (2016)

Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy
por: Fan, Ruiyun, et al.
Publicado: (2023)

On the $ doublet in $
por: Astner, G, et al.
Publicado: (1970)

Correction: Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum
por: Yew, Kok-Hooi, et al.
Publicado: (2013)

Correction: Influence of platinum harmonized textile on neuromuscular, systemic and subjective recovery
por: Zinke, Fridolin, et al.
Publicado: (2018)

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2022)

Correction to: Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives
por: Tokunaga, Masanori, et al.
Publicado: (2020)

Protocol for Identification and Removal of Doublets with DoubletDecon
por: DePasquale, Erica A.K., et al.
Publicado: (2020)

Correction: Current practices in ICU delirium management: a prospective multicenter study in the Netherlands
por: Trogrlic, Z, et al.
Publicado: (2013)

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer
por: Nakao, Akira, et al.
Publicado: (2022)

Advances in the design of the SuperB final doublet
por: Paoloni, E, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4ntsj2u046bet6s81j24ttk9n3